Combination creates a diversified biopharmaceutical company with a robust product pipeline targeting rare, unmet medical needs in oncology Pipeline led by two late-stage, Phase 3-ready cancer therapeutics – VAL-083 for… Read More
– Builds on CSL Behring’s promise and commitment to the transplant community – Deal accelerates the addition of clazakizumab, an anti-IL6 MAB currently in phase III development for treatment of… Read More
VICTORIA, British Columbia–(BUSINESS WIRE)– Aurinia Pharmaceuticals Inc. (Nasdaq:AUPH / TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple indications, announced that additional safety… Read More
The new company raises initial capital to develop transmembrane peptides against GPCRs to address high unmet needs. MONTREAL, June 8, 2020 /CNW Telbec/ – CTI Life Sciences, along with partners adMare BioInnovations, Domain… Read More
– All pre-specified subgroup analyses in the pivotal trial favored voclosporin over placebo – VICTORIA, British Columbia–(BUSINESS WIRE)–Aurinia Pharmaceuticals Inc. (Nasdaq:AUPH / TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical… Read More
